Residency · Residency · Geriatrics

Pain Management in Older Adults

Introduction

Chronic pain is one of the most prevalent and consequential conditions in the geriatric population, affecting 50 to 75 percent of community-dwelling elderly and up to 80 percent of residents in long-term care facilities. Despite its ubiquity, pain in older adults is systematically underdiagnosed and undertreated, particularly in patients with cognitive impairment. Studies have demonstrated that approximately 50 percent of dementia patients with identifiable pain sources receive no analgesia, a failure that reflects both the difficulty of pain assessment in non-verbal patients and the persistent misconception that elderly patients experience less pain or that pain is an inevitable accompaniment of aging.

The consequences of untreated pain extend far beyond subjective suffering. Uncontrolled pain drives a cascade of adverse outcomes including depression, anxiety, insomnia, functional decline, falls, social isolation, delirium, and profoundly diminished quality of life. Simultaneously, age-related changes in pharmacokinetics and pharmacodynamics increase both the sensitivity to analgesic medications and the risk of adverse drug effects, creating a narrow therapeutic window that demands careful, individualized prescribing. The WHO analgesic ladder remains a useful conceptual framework for pain management but must be substantially adapted to account for the unique pharmacological vulnerabilities of the geriatric patient.

Pain Assessment

In Cognitively Intact Patients

Self-report is the gold standard for pain assessment, reflecting the fundamental clinical principle that pain is whatever the patient says it is. Several validated scales are available for use in cognitively intact elderly patients. The Numeric Rating Scale, which asks patients to rate their pain from 0 to 10, is the most commonly employed. The Visual Analog Scale uses a 100-millimeter line on which the patient marks their pain intensity. The Verbal Descriptor Scale, which offers categorical options of none, mild, moderate, and severe, may be easier for some elderly patients to use, particularly those with limited numeracy. The Brief Pain Inventory provides a multidimensional assessment that includes pain interference with function, an evaluation that is particularly important in the geriatric context where functional preservation is a primary treatment goal.

A comprehensive pain assessment in the elderly goes beyond intensity ratings to include the location, quality, and timing of pain; aggravating and alleviating factors; the impact of pain on functional capacity and daily activities; and the effect on mood and sleep. This multidimensional assessment guides treatment selection and enables monitoring of treatment response across clinically meaningful outcomes.

In Cognitively Impaired/Non-Verbal Patients

The inability to self-report pain does not mean that a patient does not experience pain. The prevalence of pain-causing conditions is equally high in patients with dementia as in cognitively intact elderly. Behavioral observation tools have been developed to identify pain through observable indicators. The Pain Assessment in Advanced Dementia scale (PAINAD) evaluates five domains: breathing patterns, negative vocalization, facial expression, body language, and consolability, generating a score from 0 to 10 with a score of 2 or above suggesting the presence of pain. The Abbey Pain Scale incorporates 6 items and was designed specifically for end-of-life settings. Behavioral indicators of pain include facial grimacing, guarding, bracing, moaning, agitation, resistance to care, withdrawal from social interaction, and changes in appetite or sleep patterns.

When pain is suspected but assessment remains equivocal, an empirical analgesic trial provides both diagnostic and therapeutic value. The administration of scheduled acetaminophen at 1 gram three times daily for 48 to 72 hours, followed by reassessment of the target behaviors, offers a safe and informative approach. If behavior improves with the analgesic trial, pain was likely present and should be managed accordingly.

Comprehensive Pain Assessment

A thorough pain assessment integrates the patient's medical history, identifying conditions known to cause pain such as arthritis, neuropathy, cancer, fractures, and spinal stenosis. A complete medication review evaluates current analgesics, previous therapeutic trials, and adverse effects encountered. Functional assessment quantifies the impact of pain on activities of daily living, mobility, and social participation. Psychological assessment identifies comorbid depression, anxiety, pain catastrophizing, and fear-avoidance behaviors that amplify pain perception and disability. Sleep assessment recognizes the bidirectional relationship between pain and sleep disturbance, with each condition exacerbating the other.

Age-Related Pharmacological Changes

Pharmacokinetic Changes

The aging process introduces multiple pharmacokinetic alterations that affect drug handling in clinically important ways. Absorption from the gastrointestinal tract is generally preserved, though slower gastric emptying may delay the onset of drug action without significantly reducing overall bioavailability. Distribution is altered by the increase in body fat and decrease in total body water and lean body mass that accompany aging. Lipophilic drugs such as fentanyl and diazepam distribute into enlarged fat stores, producing prolonged duration of action. Hydrophilic drugs such as morphine distribute into reduced water volume, resulting in higher plasma concentrations for a given dose.

Hepatic metabolism undergoes significant age-related decline, with hepatic blood flow decreasing by approximately 40 percent and cytochrome P450 enzyme activity declining, with phase I metabolism affected more than phase II. These changes have direct clinical implications for specific analgesic agents. Codeine requires conversion to morphine via CYP2D6 for analgesic activity, but CYP2D6 activity is genetically variable: 7 to 10 percent of individuals are poor metabolizers who derive no analgesic benefit from codeine, while 1 to 3 percent are ultra-rapid metabolizers who are at risk for toxicity. Tramadol shares this CYP2D6 dependency, making its analgesic effect unpredictable in the elderly.

Renal elimination is reliably diminished with aging, with the glomerular filtration rate declining by approximately 0.75 mL/min per year. This has critical implications for drugs with active metabolites, particularly morphine-6-glucuronide (the active metabolite of morphine) and normeperidine (the neurotoxic metabolite of meperidine), which accumulate in renal impairment and can cause prolonged sedation, respiratory depression, and seizures.

Pharmacodynamic Changes

Beyond pharmacokinetic alterations, the aging nervous system demonstrates increased sensitivity to centrally acting drugs including opioids, benzodiazepines, and anticonvulsants. Reduced homeostatic reserve amplifies the risk of hypotension, respiratory depression, constipation, and sedation. Altered pain processing, including decreased descending inhibitory modulation of pain signals, may contribute to both the increased prevalence of chronic pain and the enhanced response to analgesic medications in elderly patients.

<image>A comprehensive pain assessment flowchart for elderly patients. Start with "Pain suspected in elderly patient." First branch: "Can patient self-report?" If YES → use NRS (0-10) or Verbal Descriptor Scale; assess location, quality, intensity, timing, functional impact. If NO (cognitive impairment, non-verbal) → behavioral observation using PAINAD scale (show the 5 items with scoring criteria). If PAINAD ≥2 or behavioral indicators present → "Empirical analgesic trial: scheduled acetaminophen 1g TID for 48-72 hours." If behavior improves → "Pain confirmed — continue and optimize treatment." If uncertain → reassess, consider other causes of distress. Include a sidebar showing age-related pharmacological changes affecting drug handling: increased body fat (prolonged lipophilic drug effect), decreased renal function (metabolite accumulation), decreased hepatic metabolism (higher drug levels), increased CNS sensitivity (enhanced opioid effect). Include the PAINAD scale items in a quick-reference table format.</image>

Non-Pharmacological Management (Essential Foundation)

Physical Approaches

Non-pharmacological interventions form the essential foundation of pain management in the elderly and should be incorporated into every treatment plan regardless of the severity of pain or the concurrent use of pharmacotherapy. Physical therapy, encompassing therapeutic exercise, stretching, and strengthening programs, has the strongest evidence base for chronic low back pain and osteoarthritis. Occupational therapy contributes through joint protection techniques, adaptive equipment provision, and activity modification strategies that enable continued function despite pain. Heat therapy using superficial heat sources such as heating pads and warm packs provides effective symptom relief for musculoskeletal pain, though caution is required in patients with diminished sensation to avoid burns. Cold therapy is appropriate for acute injuries and inflammatory conditions.

Transcutaneous electrical nerve stimulation (TENS) has modest evidence supporting its use in osteoarthritis and neuropathic pain and offers the advantages of safety, non-invasiveness, and absence of drug interactions. Acupuncture has demonstrated benefit for chronic low back pain, knee osteoarthritis, and headache in Cochrane reviews. Massage therapy reduces pain and anxiety, is safe, and is particularly valued in long-term care settings where social isolation and tactile deprivation compound the pain experience.

Psychological Approaches

Among psychological interventions, cognitive behavioral therapy carries the strongest evidence for chronic pain management. CBT addresses maladaptive cognitive patterns including catastrophizing and fear-avoidance behaviors that amplify the pain experience and perpetuate disability. Mindfulness-based stress reduction has demonstrated effectiveness for chronic pain and can be adapted for elderly populations with modifications for sensory impairment, mobility limitations, and cognitive changes. Relaxation techniques, guided imagery, and breathing exercises provide additional accessible tools. Acceptance and commitment therapy, which focuses on psychological flexibility and engagement with valued activities despite pain, has a growing evidence base for chronic pain conditions.

Integrative Approaches

Tai chi has been shown in Cochrane review to reduce pain and improve function in patients with knee osteoarthritis, while offering the additional benefits of improved balance and fall prevention. Yoga, when adapted for elderly participants, improves flexibility, strength, and pain. Music therapy reduces pain perception and analgesic requirements through mechanisms that likely involve both distraction and endorphin release.

Pharmacological Management

Non-Opioid Analgesics

Acetaminophen — First-Line

Acetaminophen is the recommended first-line analgesic for musculoskeletal pain in elderly patients, endorsed by the American Geriatrics Society for this indication. It should be prescribed at a dose of 500 to 1000 mg every 6 to 8 hours, with a maximum daily dose of 3 grams in healthy elderly patients and 2 grams per day in patients with hepatic impairment, alcohol use, or malnutrition. Acetaminophen is safe in chronic kidney disease, produces no gastrointestinal toxicity, and carries no cardiovascular risk, attributes that distinguish it from NSAIDs and make it particularly suitable for geriatric use. Its primary limitations are a ceiling effect on analgesic efficacy and modest effectiveness for moderate-to-severe pain. Hepatotoxicity is a risk with doses exceeding 4 grams per day, chronic alcohol use, malnutrition (which depletes hepatic glutathione stores), and pre-existing hepatic disease. Acetaminophen should be administered on a scheduled basis rather than as-needed for chronic pain, as consistent dosing provides more reliable pain control.

NSAIDs — Use with Extreme Caution

The American Geriatrics Society 2009 pain management guidelines recommend avoiding oral NSAIDs in elderly patients when possible, reflecting the substantial and multisystemic risk profile of these agents in older adults. Gastrointestinal bleeding risk is 2- to 4-fold higher in elderly patients and increases further with concurrent Helicobacter pylori infection, anticoagulant use, and corticosteroid therapy. Cardiovascular risks include myocardial infarction and stroke, with naproxen possibly having the most favorable cardiovascular safety profile. Renal injury, including acute kidney injury, chronic kidney disease progression, and hyperkalemia, represents another major concern. NSAIDs can exacerbate hypertension and precipitate heart failure decompensation.

When an NSAID is deemed necessary, it should be prescribed at the lowest effective dose for the shortest possible duration, with a proton pump inhibitor added for gastrointestinal protection, and avoided entirely in patients with chronic kidney disease, heart failure, or concurrent anticoagulation. Topical NSAIDs, particularly diclofenac gel and patches, are strongly preferred for localized musculoskeletal pain of the knee and hand osteoarthritis. They provide analgesic efficacy comparable to oral NSAIDs at the site of application with minimal systemic absorption and substantially reduced gastrointestinal and cardiovascular risk. Both NICE and ACR guidelines recommend topical NSAIDs before oral NSAIDs for knee osteoarthritis in elderly patients.

Other Topical Agents

Capsaicin cream at concentrations of 0.025 to 0.075 percent works by depleting substance P from cutaneous nerve fibers and is useful for neuropathic pain and osteoarthritis. An initial burning sensation limits compliance but typically improves after 1 to 2 weeks of consistent application. Lidocaine 5 percent patches, applied up to 3 patches for 12 hours on followed by 12 hours off, are FDA-approved for postherpetic neuralgia and are used off-label for localized neuropathic pain. Systemic absorption is minimal, making this a safe option for elderly patients with multiple comorbidities.

Adjuvant Analgesics (Neuropathic Pain)

Anticonvulsants

Gabapentin is a first-line agent for neuropathic pain conditions including diabetic neuropathy and postherpetic neuralgia. In elderly patients, it should be initiated at 100 to 300 mg at bedtime and titrated gradually to a therapeutic range of 300 to 1200 mg three times daily. Renal dose adjustment is required. Side effects relevant to the elderly include sedation, dizziness, peripheral edema, weight gain, and a significantly increased fall risk with an odds ratio of 1.7. Abuse potential is increasingly recognized and warrants awareness. Pregabalin, started at 25 to 50 mg twice daily and titrated to 150 to 300 mg twice daily, offers more predictable pharmacokinetics than gabapentin and requires renal dose adjustment. It shares the same side effect profile and is a Schedule V controlled substance. Carbamazepine remains the first-line agent for trigeminal neuralgia, initiated at 100 mg twice daily with careful titration, but its use in the elderly is limited by drug interactions, bone marrow suppression, and hyponatremia.

Antidepressants

Duloxetine, a serotonin-norepinephrine reuptake inhibitor, is effective for diabetic neuropathy, osteoarthritis, chronic low back pain, and fibromyalgia. It is initiated at 30 mg daily for one week, then increased to 60 mg daily. It should be avoided when creatinine clearance is below 30 mL/min. Gastrointestinal side effects and modest blood pressure elevation may occur. The secondary tricyclic antidepressants nortriptyline and desipramine, starting at 10 to 25 mg at bedtime with gradual titration, are effective for neuropathic pain and are preferred over amitriptyline, which is listed in the Beers Criteria as inappropriate for elderly patients due to its potent anticholinergic properties. Even the secondary TCAs carry significant anticholinergic burden in the elderly, requiring monitoring for cognitive effects, urinary retention, orthostatic hypotension, and cardiac conduction disturbances including ECG monitoring. Venlafaxine is an alternative SNRI with less specific evidence for pain conditions but may be considered when duloxetine is not tolerated.

Opioid Analgesics

Principles of Opioid Use in Elderly

Opioids are not first-line agents for pain management in the elderly and should be reserved for moderate-to-severe pain that has not responded adequately to non-opioid strategies. The cardinal principle of geriatric opioid prescribing is to start low and go slow, initiating at 25 to 50 percent of the standard adult dose. Short-acting formulations should be used initially, with conversion to long-acting formulations only when daily requirements have been established and are stable. Scheduled dosing is preferred over as-needed regimens for ongoing chronic pain, as it provides more consistent analgesia and prevents the cycles of pain breakthrough and overmedication that characterize PRN dosing. Every opioid prescription in an elderly patient must be accompanied by a prophylactic bowel regimen from day one, as opioid-induced constipation occurs in 40 to 90 percent of patients and is both predictable and preventable. Ongoing monitoring must address sedation, respiratory depression, constipation, urinary retention, fall risk, cognitive effects, and nausea.

Preferred Opioids in Elderly

Oxycodone, starting at 2.5 mg every 4 to 6 hours, offers reliable metabolism without significant active metabolites and is well-studied in the elderly. Hydromorphone, at 0.5 to 1 mg orally every 4 to 6 hours or 0.2 to 0.4 mg intravenously, is particularly useful in patients with renal impairment because it produces less active metabolite accumulation than morphine. Morphine, at 2 to 5 mg orally every 4 hours, is a well-established agent but requires caution in chronic kidney disease because morphine-6-glucuronide accumulates, causing prolonged sedation and respiratory depression. Transdermal buprenorphine, applied as a 5 to 20 mcg/hr patch changed weekly, functions as a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it useful for chronic stable pain with no renal adjustment needed. The fentanyl patch at 12 to 25 mcg/hr every 72 hours is appropriate only for opioid-tolerant patients and carries an FDA black box warning against use in opioid-naive patients. Its pharmacokinetics are affected by fever and cachexia, both of which may alter drug delivery from the patch.

Opioids to AVOID in Elderly

Several opioids should be categorically avoided in elderly patients. Meperidine is listed in the Beers Criteria due to its neurotoxic metabolite normeperidine, which accumulates and causes seizures and delirium; it should never be used in the elderly. Codeine, due to its CYP2D6-dependent metabolism, is ineffective in poor metabolizers and potentially toxic in ultra-rapid metabolizers, making its analgesic effect unacceptably variable. Tramadol shares the CYP2D6 dependency of codeine and additionally lowers the seizure threshold, carries risk of serotonin syndrome when combined with SSRIs, has high drug interaction potential, and can cause hypoglycemia. Propoxyphene has been withdrawn from the market due to cardiac toxicity. Methadone, while effective, has complex pharmacokinetics with a highly variable half-life of 8 to 59 hours, QTc prolongation risk, and unpredictable accumulation, and should be used only by specialists experienced in its management.

Opioid-Induced Constipation (OIC)

Prevention of opioid-induced constipation begins with the first opioid dose. A stimulant laxative regimen of senna 8.6 to 17.2 mg twice daily combined with docusate 100 mg twice daily provides the foundation of prophylaxis. Osmotic laxatives such as polyethylene glycol 17 grams daily are added if stimulant laxatives prove insufficient. For refractory opioid-induced constipation, peripherally acting mu-opioid receptor antagonists (PAMORAs) offer targeted relief without crossing the blood-brain barrier and therefore without reversing analgesia. Methylnaltrexone at 8 to 12 mg subcutaneously every other day, naloxegol at 25 mg orally daily, and naldemedine at 0.2 mg orally daily are the available options in this class.

<image>A tiered pain management ladder adapted for geriatric patients. Show a modified WHO analgesic ladder with geriatric-specific modifications. Step 1 (MILD PAIN): acetaminophen 500-1000mg q6-8h (max 3g/day) + topical NSAIDs (diclofenac gel) + non-pharmacological approaches (PT, heat, TENS, CBT). Step 2 (MODERATE PAIN): add adjuvants — gabapentin/pregabalin for neuropathic pain, duloxetine for neuropathic/MSK pain, topical lidocaine for localized neuropathic pain. Step 3 (MODERATE-SEVERE PAIN): add low-dose opioid (oxycodone 2.5mg, hydromorphone 0.5mg) + bowel regimen (senna + docusate automatically). Step 4 (SEVERE PAIN): titrate opioid to effect; consider long-acting formulations; add interventional approaches (nerve blocks, epidural). On the side, show a RED "AVOID" column listing: meperidine, codeine, tramadol, oral NSAIDs long-term, amitriptyline, benzodiazepines for chronic pain, long-acting opioids in opioid-naive patients. Include a GREEN "ALWAYS" column: bowel regimen with opioids, non-pharmacological approaches at every step, reassessment schedule, functional goals. Show dose adjustments needed for CKD and hepatic impairment at each level.</image>

Interventional Approaches

Interventional pain management techniques offer targeted relief for specific pain conditions when pharmacological and non-pharmacological approaches are insufficient. Intra-articular corticosteroid injections, typically triamcinolone 40 mg into the knee or hip joint, provide benefit lasting 4 to 12 weeks for osteoarthritis and should be limited to 3 to 4 injections per year per joint to avoid cartilage degradation. Epidural steroid injections provide short-term relief for lumbar spinal stenosis and radiculopathy, with risks including dural puncture and infection. Nerve blocks, including intercostal blocks for rib fractures, femoral and fascia iliaca blocks for hip fractures, and occipital blocks for occipital neuralgia, provide targeted regional analgesia.

Radiofrequency ablation of facet joint and sacroiliac joint nerves offers longer-lasting pain relief than injection-based approaches. Spinal cord stimulation, using an implanted device to modulate pain signals, is reserved for refractory neuropathic pain. Vertebroplasty and kyphoplasty for painful vertebral compression fractures remain debated, with the VERTOS II trial demonstrating benefit compared with conservative treatment while the INVEST trial showed no benefit compared with a sham procedure. Selection of candidates for these procedures requires careful clinical judgment.

Key Clinical Pearls

• Acetaminophen is the first-line analgesic for musculoskeletal pain in elderly — it is safe, effective, and should be used as scheduled (not PRN) at adequate doses (up to 3g/day)
• Topical NSAIDs (diclofenac gel) should be used BEFORE oral NSAIDs for localized joint pain — they provide equivalent efficacy with far less systemic risk
• AVOID meperidine, codeine, and tramadol in ALL elderly patients — each has a specific mechanism of harm in this population
• Non-verbal patients with dementia experience pain just as frequently as cognitively intact patients — behavioral assessment (PAINAD) and empirical analgesic trials are essential
• Every opioid prescription in an elderly patient must include a bowel regimen from day one — opioid-induced constipation is predictable and preventable
• Gabapentin and pregabalin are first-line for neuropathic pain but significantly increase fall risk in elderly (OR 1.7) — start at very low doses and titrate slowly
• Non-pharmacological approaches (PT, CBT, exercise, TENS) should be part of EVERY pain management plan — they are underutilized and have strong evidence

References

1. Abdulla A, Adams N, Bone M, et al. Guidance on the management of pain in older people. Age Ageing. 2013;42(Suppl 1):i1-i57.
2. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50(Suppl 6):S205-S224.
3. Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9-15.
4. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists. J Pain. 2016;17(2):131-157.
5. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.

Read this lecture as Markdown